Chiyoda, Japan Dai-ichi Life is the famous Corporate Investor, which was founded in 1902. The company was established in Asia in Japan. The leading representative office of defined Corporate Investor is situated in the Tokyo.
The top activity for fund was in 2018. The common things for fund are deals in the range of 10 - 50 millions dollars. The fund is constantly included in less than 2 investment rounds annually.
The fund has exact preference in a number of founders of portfolio startups. Among the most popular portfolio startups of the fund, we may highlight Neurotrack, CureApp, Meltin MMI. For fund there is a match between the location of its establishment and the land of its numerous investments - Japan. Among the most successful fund investment fields, there are Robotics, Information Technology. Besides, a startup needs to be aged 4-5 years to get the investment from the fund.
The typical case for the fund is to invest in rounds with 4-5 participants. Despite the Dai-ichi Life, startups are often financed by Real Tech Fund, Rohto Pharmaceutical, ANA Holdings. The meaningful sponsors for the fund in investment in the same round are SBI Investment, Rohto Pharmaceutical, Sompo Holdings. In the next rounds fund is usually obtained by Rohto Pharmaceutical, Mirai Creation Fund, Meiji Yasuda Life Insurance Co..
Related Funds
Notable deals
| Company | Industry | Round Size | Date | Investors | Location |
COMICSMART | $25M | 06 Aug 2024 | Tokyo, Kantō, Japan | ||
GITAI | $36M | 24 May 2023 | Chiyoda, Japan | ||
Ubie | $26M | 22 Aug 2022 | Chiyoda, Japan | ||
YuLife | $120M | 07 Jul 2022 | London, England, United Kingdom | ||
Wassha | $10M | 12 Jun 2022 | Tanzania | ||
Noile-Immune Biotech | $21M | 22 Mar 2021 | Chiyoda, Japan | ||
GITAI | $16M | 02 Mar 2021 | Chiyoda, Japan | ||
GITAI | $17M | 01 Mar 2021 | Japan, Chiyoda | ||
| 05 Feb 2021 | Minato, Japan |
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.
Full teamIndustries heatmapStages heatmapGeorgaphy breakdownCoinvestorsPortfolio analysisPerformance indexesLatest highlights
Unlock all data Latest deals
| Company | Industry | Round Size | Date | Investors | Location |
COMICSMART | $25M | 06 Aug 2024 | Tokyo, Kantō, Japan | ||
GITAI | $36M | 24 May 2023 | Chiyoda, Japan | ||
Ubie | $26M | 22 Aug 2022 | Chiyoda, Japan | ||
YuLife | $120M | 07 Jul 2022 | London, England, United Kingdom | ||
Wassha | $10M | 12 Jun 2022 | Tanzania | ||
Noile-Immune Biotech | $21M | 22 Mar 2021 | Chiyoda, Japan | ||
GITAI | $16M | 02 Mar 2021 | Chiyoda, Japan | ||
GITAI | $17M | 01 Mar 2021 | Japan, Chiyoda | ||
| 05 Feb 2021 | Minato, Japan |
